Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Topotecan via CED in High Grade Glioma
NCT03927274Phase 1Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of topotecan in high-grade glioma (HGG), sponsored by Moffitt Cancer Center. Primary endpoint: Distribution of topotecan in tumor tissue at Day 1. Started Jun 2019; status: terminated.
02
Drugs
topotecan
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT03927274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927274.